Evidence map›Paper›PMID 28932952›Full record

ArticleInternational urology and nephrology2017

Survival of metastatic renal cell carcinoma patients continues to improve over time, even in targeted therapy era.

Michele Marchioni, Marco Bandini, Raisa S Pompe, Zhe Tian, Tristan Martel, Anil Kapoor, Luca Cindolo, Francesco Berardinelli, Alberto Briganti, Shahrokh F Shariat and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in International urology and nephrology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Observational
  5. Review
  6. Effect of external beam radiotherapy on second primary cancer risk after radical prostatectomy.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2020
    Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Michele MarchioniCancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada. mic.marchioni@gmail.com.ORCID http://orcid.org/0000-0002-1702-4127
Marco BandiniCancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada.
Raisa S PompeCancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada.
Zhe TianCancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada.
Tristan MartelCancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada.
Anil KapoorDivision of Urology, McMaster University, Hamilton, ON, Canada.
Luca CindoloDepartment of Urology, ASL Abruzzo 2, Chieti, Italy.
Francesco BerardinelliDepartment of Urology, ASL Abruzzo 2, Chieti, Italy.
Alberto BrigantiDivision of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy.
Shahrokh F ShariatDepartment of Urology, Medical University of Vienna, Vienna, Austria.
Luigi SchipsDepartment of Urology, ASL Abruzzo 2, Chieti, Italy.
Pierre I KarakiewiczCancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo examine the effect of diagnosis year, defined as contemporary (2010-2014), intermediate (2006-2009) and historical (2001-2005) on cancer-specific mortality (CSM) in patients with metastatic renal cell carcinoma (mRCC).

methodsWithin Surveillance, Epidemiology, and End Results registry (2001-2014), we identified patients with mRCC. Cumulative incidence and competing risks regression (CRR) models examined CSM, after accounting for other-cause mortality. Finally, we performed subgroup analyses according to histological subtype: clear-cell mRCC (ccmRCC) versus non-ccmRCC.

resultsWe identified 15,444 patients with mRCC. Of those, 41.0, 28.7 and 30.3% were diagnosed, respectively, in the contemporary, intermediate and historical years. Of all, 47.1, 5.3 and 47.6% were, respectively, ccmRCC, non-ccmRCC and other mRCC histological variants [sarcomatoid mRCC, cyst-associated mRCC, collecting duct carcinoma and mRCC not otherwise specified (NOS)]. Overall, 24-month CSM rates were, respectively, 61.0, 63.7 and 67.3% in contemporary, intermediate and historical patients. In all patients, multivariable CRR models exhibited higher CSM in intermediate (HR 1.11; p < 0.001) and historical patients (HR 1.24; p < 0.001) than in contemporary patients. Multivariable CRR models focusing on ccmRCC yielded virtually the same results. However, multivariable CRR models focusing on non-ccmRCC showed no CSM differences according to diagnosis year (all p ≥ 0.3).

conclusionThe introduction of new therapeutic agents resulted in CSM-free survival improvement over study time. However, this effect exclusively applies to patients with ccmRCC, but not to those with non-ccmRCC. This observation is in agreement with established efficacy of systemic therapies for ccmRCC, but lesser efficacy of these agents for non-ccmRCC.

Indexed as

Models, StatisticalAdolescentAdultAgedAged, 80 and overCarcinoma, Renal CellFemaleHumansKidney NeoplasmsMaleMiddle AgedMolecular Targeted TherapyMultivariate AnalysisRegression AnalysisSEER ProgramSurvival RateCancer-specific mortalityCompeting risks analysisKidney cancerMetastaticTargeted therapy

Identifiers

PMID28932952

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.